Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. - Wikidata - awgldk - TriplyDB

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

http://www.wikidata.org/entity/Q46424154

about

The role of c-kit and imatinib mesylate in uveal melanoma.Targeted drugs in small-cell lung cancer Genomic profiling of small-cell lung cancer: the era of targeted therapies KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials.A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.Treatment options for small cell lung cancer - do we have more choice?Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies Small cell lung cancer: where do we go from here?Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.Small cell lung cancer: therapies and targets Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.Targeted therapies in small cell lung cancer: a review Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer.Small cell lung cancer: will recent progress lead to improved outcomes?Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Tailor-made chemotherapy for non-small cell lung cancer patients.Targeted therapies in small cell lung cancer Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.Cancer therapeutics: an update on its effects on oral health.Targeted therapies in small-cell lung cancer.Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.The development of targeted therapy in small cell lung cancer.Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Update on new drugs in small cell lung cancer.Novel strategies for the treatment of small-cell lung carcinoma.Management of small cell lung cancer: recent developments for optimal care.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy.Imatinib mesylate in desmoplastic small round cell tumors.Histological specificity of alterations and expression of KIT and KITLG in non-small cell lung carcinoma.Neuroendocrine Carcinoma of the Endometrium: A Clinicopathologic Study of 25 Cases.Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations.Second-line treatments of small-cell lung cancers.Imatinib mesylate in thymic epithelial malignancies.Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy?Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.

P2860

Q21245647-DB96A128-981B-470A-9A3C-4CC757E1C07E Q26767017-8AD65DFB-2313-402A-965E-BE8520F2DD0A Q26826915-4E1DBC64-6AC4-455D-A6DE-AFC935863405 Q28484518-41D470CD-8DCB-4F90-9921-5FAA25CA6B27 Q30235046-ABE2F7F7-D83A-435C-BE1A-AA1708512159 Q33416075-15A2C7DB-B95E-474F-AB49-482F669F3F04 Q33723735-3139F97F-94AD-4281-AD84-05592A22426B Q33840177-6DDA6FA4-BCFE-4E0D-AEC3-D111645CEEB4 Q33872327-D9401D92-EA8C-4D90-911A-141C951F9845 Q34013850-615F0DF1-3C61-4B07-8359-FA6AC1439075 Q34250859-72329D71-C502-4CF9-BE5F-EEDDD1F09372 Q34630373-446956DA-3B5D-4809-8320-2E63E057659A Q35076234-363D4BE3-3570-4EEE-A132-174516A50E44 Q35082777-41543FA4-6C09-465C-B2CA-20D8847DB428 Q35836257-556753BE-D5C6-4967-9EFE-E13ED99E7837 Q36067817-EFC5B932-92DC-4FAF-9434-7D167DF7DB8A Q36281852-26ADCEE1-C944-4205-BC82-175510EF0ACC Q36376439-23A2BB51-9F06-4265-BAFC-6D9F27891879 Q36430761-661FC048-6E10-429E-AABC-F0078F6671C5 Q36475811-07257AD2-303F-417E-B715-F1F114F1EB7E Q36690945-58C4A716-B3C9-4231-9EEB-751E9AE33B7F Q36809165-CDC3A52E-AEF9-4FF0-8E33-5A252ACEDC6C Q36897340-844044C6-30B9-48C3-8213-F4A9B6D87A4F Q36911934-90080A00-6D52-413C-AB99-CFF0160ADD54 Q37127932-835CDBBD-898D-47AC-8136-EAB9BF9BC6E4 Q37132792-FAE0C51E-F0A2-4E7C-8F43-14FE143B0D5B Q37590339-3F7A61E9-BFB8-45F1-AC9D-06B4DC8C99C7 Q37851992-E4BEB9E6-1C43-49A0-8009-E175CDFA4297 Q37892341-8B36EF1C-FDFD-4962-B19B-EECFC350A2D0 Q37987205-C702538E-8697-475C-B23E-1859CDFDEE08 Q38113988-77CCC1FB-D316-4BCF-8BD7-876730CAF2D4 Q38364522-8D569BC3-5905-4AD3-9199-65C176EA75CA Q38673826-C829BB7F-7C17-49A8-B340-3D76412C49FE Q39353163-E3ACD885-847F-4481-83E8-F9174B98591C Q40870680-DDD7FADC-6090-4539-A7F4-D683BC6177B2 Q43894262-683BF461-B9F8-4C01-8820-F0B2848A4047 Q47789861-E75800BF-A691-43D0-89A0-1482D0744529 Q51024689-0E35F885-9B35-460C-87D6-1C5D7903D3B0 Q53588556-B6DA4CFD-2FEF-4B59-9616-CE7728E8492C Q53740020-75E233F6-C5AB-446C-8E77-9D2A21354845

P2860

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

http://www.wikidata.org/entity/Q46424154

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Imatinib mesylate lacks activi ...... in: a phase II clinical trial.

@en

Imatinib mesylate lacks activi ...... in: a phase II clinical trial.

@nl

type

label

Imatinib mesylate lacks activi ...... in: a phase II clinical trial.

@en

Imatinib mesylate lacks activi ...... in: a phase II clinical trial.

@nl

prefLabel

Imatinib mesylate lacks activi ...... in: a phase II clinical trial.

@en

Imatinib mesylate lacks activi ...... in: a phase II clinical trial.

@nl

P1433

Q46424154-63F6BFDE-B6A4-4E70-8564-42C2A43AA204

P1476

Q46424154-612306D3-21BC-49F5-9A68-3C81B5C6FB46

P2093

Q46424154-1CF923AA-B8FE-4F6D-BDD0-87571C054EC7

Q46424154-22EA802D-7974-4901-87BF-17B6E4E16204

Q46424154-6B8496F4-20EC-4395-AB03-A98A4A17E558

Q46424154-A16EDD76-131F-4DB8-AC7B-B976195C73D6

Q46424154-A325903A-B123-4721-852F-56C12C97EC1C

Q46424154-B5256B66-BA8E-4E1E-8044-082151389212

Q46424154-C3819D2C-B870-4B64-AD56-D72B4BA72673

Q46424154-D75F626E-27D5-4160-8589-C407A19096BD

Q46424154-DE34C3E8-540E-4A88-925F-A3412CAFDC09

Q46424154-EC1088C4-798E-42B3-8A7D-C3D242F4D656

P304

Q46424154-FEC9BBF5-755F-4AC3-BC8B-AD08244A0455

P31

Q46424154-F83059E6-FD55-40D8-96B1-730E680845A2

P356

Q46424154-0EEF1F94-8444-4FC6-BA25-0D4034939AEB

P407

Q46424154-E4C6292B-ECF1-4BCE-9AD6-7D9FFF4D4ADB

P433

Q46424154-8EB53840-20F7-4FCD-A857-EF7CB1951DA2

P478

Q46424154-51EB7AE9-35B7-4C55-A7C4-DD2A54F1465B

P50

Q46424154-D303F0D3-0CBC-4E09-9231-234B4E2C851A

P577

Q46424154-7B71DC1F-7D83-429B-9C85-D04E8CC5C846

P5875

Q46424154-71F04DC4-142A-4801-AE58-D83C99DA5A94

P698

Q46424154-F7EEF469-81C8-4DCE-AEA5-565999B01529

P921

Q46424154-45C4F6FB-0644-4709-83F9-CAB67E4D1CFF

P356

P1433

P1476

Imatinib mesylate lacks activi ...... in: a phase II clinical trial.

@en

P2093

Barbara Pizzo

http://www.w3.org/2001/XMLSchema#string

Christopher G Azzoli

http://www.w3.org/2001/XMLSchema#string

John P Crapanzano

http://www.w3.org/2001/XMLSchema#string

Jorge Gomez

http://www.w3.org/2001/XMLSchema#string

Lee M Krug

http://www.w3.org/2001/XMLSchema#string

Leslie Tyson

http://www.w3.org/2001/XMLSchema#string

Megan Dunne

http://www.w3.org/2001/XMLSchema#string

Naiyer Rizvi

http://www.w3.org/2001/XMLSchema#string

Robert T Heelan

http://www.w3.org/2001/XMLSchema#string

Vincent A Miller

http://www.w3.org/2001/XMLSchema#string

P304

2128-2131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.21000

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7923212

http://www.w3.org/2001/XMLSchema#string

P698

15812822

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial